{"title":"抗艾滋病药物。","authors":"E De Clercq","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>There are, at present, 22 compounds which have been formally approved (by the US Food and Drug Administration) for the treatment of HIV infections (AIDS). According to their point of intervention with the HIV replicative cycle, these compounds can be classified in 5 categories: (1) NRTIs (nucleoside reverse transcriptase inhibitors): azidothymidine, didanosine, zalcitabine, stavudine, lamivudine, abacavir and emtricitabine; (2) NtRTIs (nucleotide reverse transcriptase inhibitors): tenofovir, administered as its oral prodrug form TDF (tenofovir disoproxil fumarate); (3) NNRTIs (non-nucleoside reverse transcriptase inhibitors): nevirapine, delavirdine and efavirenz; (4) PIs (HIV protease inhibitors): saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, lopinavir, atazanavir, fosamprenavir, tipranavir and darunavir; and (5) FIs (fusion inhibitors): enfuvirtide. Starting from the drugs which are currently available for the treatment of AIDS, numerous combinations could be envisaged. Drug combinations are, in principle, aimed at obtaining synergism between the compounds (reasonably expected if they act by different mechanisms), while reducing the likelihood for drug resistance development. Such anti-HIV drug combination regimes were initiated about 10 years ago and have been generally referred to as HAART (for highly active antiretroviral therapy). While HAART originally consisted of a pill burden of twenty (or more) pills per day, this has been gradually diminished over the past few years, and, since July 2006, a all-in-one pill (Atripla) has become available, which contains three anti-HIV drugs (tenofovir disoproxil fumarate, emtricitabine and efavirenz) to be taken as a single pill only once daily. Given the information that has been acquired on the therapeutic use (efficacy, safety) of tenofovir disoproxil fumarate over the past five years, it would now seem mandatory to further consider the prophylactic use of TDF [and its combination with emtricitabine (Truvada) and/or Atripla], as a single daily pill to prevent HIV infection.</p>","PeriodicalId":76790,"journal":{"name":"Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie","volume":"69 2","pages":"81-104"},"PeriodicalIF":0.0000,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Anti-HIV drugs.\",\"authors\":\"E De Clercq\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>There are, at present, 22 compounds which have been formally approved (by the US Food and Drug Administration) for the treatment of HIV infections (AIDS). According to their point of intervention with the HIV replicative cycle, these compounds can be classified in 5 categories: (1) NRTIs (nucleoside reverse transcriptase inhibitors): azidothymidine, didanosine, zalcitabine, stavudine, lamivudine, abacavir and emtricitabine; (2) NtRTIs (nucleotide reverse transcriptase inhibitors): tenofovir, administered as its oral prodrug form TDF (tenofovir disoproxil fumarate); (3) NNRTIs (non-nucleoside reverse transcriptase inhibitors): nevirapine, delavirdine and efavirenz; (4) PIs (HIV protease inhibitors): saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, lopinavir, atazanavir, fosamprenavir, tipranavir and darunavir; and (5) FIs (fusion inhibitors): enfuvirtide. Starting from the drugs which are currently available for the treatment of AIDS, numerous combinations could be envisaged. Drug combinations are, in principle, aimed at obtaining synergism between the compounds (reasonably expected if they act by different mechanisms), while reducing the likelihood for drug resistance development. Such anti-HIV drug combination regimes were initiated about 10 years ago and have been generally referred to as HAART (for highly active antiretroviral therapy). While HAART originally consisted of a pill burden of twenty (or more) pills per day, this has been gradually diminished over the past few years, and, since July 2006, a all-in-one pill (Atripla) has become available, which contains three anti-HIV drugs (tenofovir disoproxil fumarate, emtricitabine and efavirenz) to be taken as a single pill only once daily. Given the information that has been acquired on the therapeutic use (efficacy, safety) of tenofovir disoproxil fumarate over the past five years, it would now seem mandatory to further consider the prophylactic use of TDF [and its combination with emtricitabine (Truvada) and/or Atripla], as a single daily pill to prevent HIV infection.</p>\",\"PeriodicalId\":76790,\"journal\":{\"name\":\"Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie\",\"volume\":\"69 2\",\"pages\":\"81-104\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2007-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
目前,有22种化合物已被(美国食品和药物管理局)正式批准用于治疗HIV感染(艾滋病)。根据其对HIV复制周期的干预点,这些化合物可分为5类:(1)核苷类逆转录酶抑制剂(NRTIs):阿齐多苷、二腺苷、齐西他滨、他夫定、拉米夫定、阿巴卡韦和恩曲他滨;(2) NtRTIs(核苷酸逆转录酶抑制剂):替诺福韦,作为其口服前药形式TDF(富马酸替诺福韦二氧吡酯);(3) NNRTIs(非核苷类逆转录酶抑制剂):奈韦拉平、德拉韦林和依非韦伦;(4) PIs (HIV蛋白酶抑制剂):沙奎那韦、利托那韦、茚地那韦、奈非那韦、安普雷那韦、洛匹那韦、阿扎那韦、福samprenavir、替那韦、darunavir;(5) FIs(融合抑制剂):恩福韦肽。从目前可用于治疗艾滋病的药物开始,可以设想多种组合。原则上,药物组合旨在获得化合物之间的协同作用(如果它们通过不同的机制起作用,则合理预期),同时减少产生耐药性的可能性。这种抗艾滋病毒药物组合方案大约在10年前开始,通常被称为HAART(高活性抗逆转录病毒疗法)。虽然HAART最初包括每天20片(或更多)药丸的负担,但在过去几年中逐渐减少,并且自2006年7月以来,一种多功能药丸(Atripla)已经可用,其中含有三种抗艾滋病毒药物(富马酸替诺福韦二氧吡酯,恩曲他滨和依非韦伦),每天只需服用一次。鉴于在过去五年中关于富马酸替诺福韦二氧吡酯治疗用途(有效性和安全性)的信息,现在似乎有必要进一步考虑预防性使用TDF[及其与恩曲他滨(特鲁瓦达)和/或阿特里普拉联合使用],作为每日一次的药丸来预防HIV感染。
There are, at present, 22 compounds which have been formally approved (by the US Food and Drug Administration) for the treatment of HIV infections (AIDS). According to their point of intervention with the HIV replicative cycle, these compounds can be classified in 5 categories: (1) NRTIs (nucleoside reverse transcriptase inhibitors): azidothymidine, didanosine, zalcitabine, stavudine, lamivudine, abacavir and emtricitabine; (2) NtRTIs (nucleotide reverse transcriptase inhibitors): tenofovir, administered as its oral prodrug form TDF (tenofovir disoproxil fumarate); (3) NNRTIs (non-nucleoside reverse transcriptase inhibitors): nevirapine, delavirdine and efavirenz; (4) PIs (HIV protease inhibitors): saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, lopinavir, atazanavir, fosamprenavir, tipranavir and darunavir; and (5) FIs (fusion inhibitors): enfuvirtide. Starting from the drugs which are currently available for the treatment of AIDS, numerous combinations could be envisaged. Drug combinations are, in principle, aimed at obtaining synergism between the compounds (reasonably expected if they act by different mechanisms), while reducing the likelihood for drug resistance development. Such anti-HIV drug combination regimes were initiated about 10 years ago and have been generally referred to as HAART (for highly active antiretroviral therapy). While HAART originally consisted of a pill burden of twenty (or more) pills per day, this has been gradually diminished over the past few years, and, since July 2006, a all-in-one pill (Atripla) has become available, which contains three anti-HIV drugs (tenofovir disoproxil fumarate, emtricitabine and efavirenz) to be taken as a single pill only once daily. Given the information that has been acquired on the therapeutic use (efficacy, safety) of tenofovir disoproxil fumarate over the past five years, it would now seem mandatory to further consider the prophylactic use of TDF [and its combination with emtricitabine (Truvada) and/or Atripla], as a single daily pill to prevent HIV infection.